Benzodiazepines and anxiety disorders: a review for the practicing physician
The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
UNLABELLED: OBJECTIVES AND SCOPE: The objective of this article is to briefly review for practicing clinicians differences among the benzodiazepines (BZDs) that are commonly used to treat anxiety, the efficacy of BZDs in various anxiety disorders, and potential safety issues associated with BZDs, including adverse events, tolerance, dependence, and withdrawal. METHODOLOGY: Information for this review was obtained using literature searches through PubMed (1966-2004), Google, and the Food and Drug Administration Catalog of Approved Drugs. Data sources were searched for information regarding anxiety disorders and the safety and efficacy of BZDs. Wherever possible and appropriate, information from randomized controlled trials was given priority. FINDINGS: Benzodiazepines have demonstrated efficacy in treating patients with anxiety disorders, with varying degrees of efficacy. Use of BZDs is advantageous because they have a quick onset of action and are generally well tolerated. Extended-release formulations of BZDs may be particularly advantageous in some patients with anxiety as they allow for maximization of a drug's therapeutic window with consistent serum drug concentrations. CONCLUSIONS: BZDs remain a mainstay in the treatment of anxiety, as both monotherapy and adjunctive therapy. Factors to consider prior to prescribing a BZD include the patient's diagnosis, as well as drug characteristics, including the potential for interactions with other drugs, the risk of dependence and withdrawal, and the required frequency of dosing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Trier Social Stress Test (TSST) is regarded as the gold standard in simulating a stressful social situation”
In the citing paper
“That previous study focused on women with SAD with baseline LSAS score ≥60; average SUDS rating during the performance of a TSST was 80.7 when treated with placebo. 9”
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Posttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Psychotropic Drug Use and the Risk of Hip Fracture
Ray, W. A., Griffin, M. R., Schaffner, W., Baugh, D. K., & Melton, L. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702123160702 · Cited by 1,000
Benzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture
Ray, W. A. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430230088031 · Cited by 548
Newer antidepressants and the cytochrome P450 system
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.311 · Cited by 482
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 412
Drug-Induced Cognitive Impairment in the Elderly
Moore, A. R., & O??Keeffe, S. T. (1999) · Drugs & Aging · doi:10.2165/00002512-199915010-00002 · Cited by 409
Cognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404
Rickels, K. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290060008 · Cited by 384
Use of benzodiazepines in anxiety disorders
Wood, A. J. J., Shader, R. I., & Greenblatt, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281907 · Cited by 341
Herings, R. M. C. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.16.1801 · Cited by 331
Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R. T., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.533 · Cited by 314
Cognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312
(2004) · PubMed · Cited by 296
Benzodiazepine Dependence A Review of the Evidence
Owen, R. T., & Tyrer, P. (1983) · Drugs · doi:10.2165/00003495-198325040-00003 · Cited by 287
Treatment of Social Phobia With Clonazepam and Placebo
DAVIDSON, J. R. T., POTTS, N., RICHICHI, E., KRISHNAN, R., FORD, S. M., SMITH, R., & WILSON, W. H. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312000-00008 · Cited by 265
Feltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., & Pande, A. C. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084032.22282.ff · Cited by 260
Ceulemans, D., Hoppenbrouwers, M.-L., Gelders, Y., & Reyntjens, A. (1985) · Pharmacopsychiatry · doi:10.1055/s-2007-1017385 · Cited by 226
(1990) · PubMed · Cited by 222
Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?
Lader, M. H. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00051-6 · Cited by 220
Diazepam and Propranolol in Panic Disorder and Agoraphobia
Noyes, R. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790140077009 · Cited by 184
Klein, E. (2002) · PubMed · Cited by 182
Otto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G. (2000) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(00)00027-x · Cited by 175
Cognitive impairment in long-term benzodiazepine users
Golombok, S., Moodley, P., & Lader, M. (1988) · Psychological Medicine · doi:10.1017/s0033291700007911 · Cited by 167
Efficacy studies of alprazolam in panic disorder.
Spiegel, D. A. (1998) · PubMed · Cited by 166
Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management
Schweizer, E., & Rickels, K. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05973.x · Cited by 163
Early Coadministration of Clonazepam With Sertraline for Panic Disorder
Goddard, A. W., Brouette, T., Almai, A., Jetty, P., Woods, S. W., & Charney, D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.681 · Cited by 156
Möller, H.-J., Volz, H.-P., Reimann, I. W., & Stoll, K.-D. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00011 · Cited by 147
WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults
Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Montgomery, S. A., Nutt, D. J., Okasha, A., Swinson, R. P., & Zohar, J. (2003) · CNS Spectrums · doi:10.1017/s1092852900006908 · Cited by 143
Michelini, S., Cassano, G., Frare, F., & Perugi, G. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-979558 · Cited by 135
Clomipramine, Clonazepam, and Clonidine Treatment of Obsessive-Compulsive Disorder
HEWLETT, W. A., VINOGRADOV, S., & AGRAS, W. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199212000-00008 · Cited by 129
Bruce, S. E., Vasile, R. G., Goisman, R. M., Salzman, C., Spencer, M., Machan, J. T., & Keller, M. B. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1432 · Cited by 127
Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
Smith, R. B., Kroboth, P. D., VanderLugt, J. T., Phillips, J. P., & Juhl, R. P. (1984) · Psychopharmacology · doi:10.1007/bf00431449 · Cited by 126
Pollack, M. H., Simon, N. M., Worthington, J. J., Doyle, A. L., Peters, P., Toshkov, F., & Otto, M. W. (2003) · Journal of Psychopharmacology · doi:10.1177/02698811030173009 · Cited by 124
Benzodiazepines with different half-life and falling in a hospitalized population
Passaro, A., Volpato, S., Romagnoni, F., Manzoli, N., Zuliani, G., & Fellin, R. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00254-7 · Cited by 122
Dünner, D. L., Ishiki, D., Avery, D., Wilson, L. G., & Hyde, T. S. (1986) · PubMed · Cited by 120
Long-term treatment of social phobia with clonazepam.
Davidson, J. R., Ford, S. M., Smith, R. D., & Potts, N. L. S. (1991) · PubMed · Cited by 116
Diazepam versus alprazolam for the treatment of panic disorder.
Noyes, R., Burrows, G. D., Reich, J. H., Judd, F. K., Garvey, M. J., Norman, T. R., Cook, B. L., & Marriott, P. F. (1996) · PubMed · Cited by 97
A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder
Hollander, E., Kaplan, A., & Stahl, S. M. (2003) · The World Journal of Biological Psychiatry · doi:10.3109/15622970309167908 · Cited by 97
Maintenance Drug Treatment for Panic Disorder: II. Short- and Long-term Outcome After Drug Taper
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130067010 · Cited by 94
WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder
Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003) · CNS Spectrums · doi:10.1017/s1092852900006945 · Cited by 93
Davidson, J. R. T. (2004) · The Journal of Clinical Psychiatry · Cited by 91
Clobazam: A Review of its Pharmacological Properties and Therapeutic Use in Anxiety
Brogden, R. N., Heel, R. C., Speight, T. M., & Avery, G. S. (1980) · Drugs · doi:10.2165/00003495-198020030-00001 · Cited by 85
Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder
Enkelmann, R. (1991) · Psychopharmacology · doi:10.1007/bf02244440 · Cited by 84
Andersch, S., Rosenberg, N. K., Kullingsjö, H., Ottosson, J. ‐., Bech, P., Bruun‐Nansen, J., Hanson, L., Lorentzen, K., Mellergård, M., Rasmussen, S., et al. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03097.x · Cited by 81
Kan, C. C., Hilberink, S. R., & Breteler, M. H. M. (2004) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2003.12.007 · Cited by 81
Nelson, J., & Chouinard, G. (1999) · PubMed · Cited by 81
Rosenbaum, J. F., Moroz, G., & Bowden, C. L. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00008 · Cited by 75
Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients
Laakmann, G., Schüle, C., Lorkowski, G., Baghai, T. C., Kuhn, K., & Ehrentraut, S. (1998) · Psychopharmacology · doi:10.1007/s002130050578 · Cited by 75
Clonazepam as an Augmenting Agent in the Treatment of Childhood-Onset Obsessive-Compulsive Disorder
Leonard, H. L., Topol, D., Bukstein, O. G., Hindmarsh, D. J., Allen, A. J., & Swedo, S. E. (1994) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199407000-00003 · Cited by 74
Benzodiazepine Dependence: Avoidance and Withdrawal
Marriott, S., & Tyrer, P. (1993) · Drug Safety · doi:10.2165/00002018-199309020-00003 · Cited by 73
Gao, P., Nixon, P. R., & Skoug, J. W. (1995) · Pharmaceutical Research · doi:10.1023/a:1016246028338 · Cited by 69
Behaviour Therapy and Benzodiazepines: Allies or Antagonists?
Wardle, J. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.156.2.163 · Cited by 68
Rickels, K., DeMartinis, N., & Aufdembrinke, B. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00004 · Cited by 68
Social anxiety disorder in review: two decades of progress
Hidalgo, R. B., Barnett, S. D., & Davidson, J. R. T. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002504 · Cited by 65
Gepirone and Diazepam in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Rickels, K., Schweizer, E., DeMartinis, N., Mandos, L., & Mercer, C. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00006 · Cited by 64
Discontinuation of Clonazepam in the Treatment of Social Phobia
Connor, K. M., Davidson, J. R. T., Potts, N. L. S., Tupler, L. A., Miner, C. M., Malik, M. L., Book, S. W., Colket, J. T., & Ferrell, F. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199810000-00004 · Cited by 64
Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam.
Charney, D. S., & Woods, S. W. (1989) · PubMed · Cited by 62
Drug related falls: a study in the French pharmacovigilance database
Souchet, E., Lapeyre‐Mestre, M., & Montastruc, J. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1038 · Cited by 59
Lorazepam Vs. Alprazolam in the Treatment of Panic Disorder
Schweizer, E., Pohl, R., Balon, R., Fox, I., Rickels, K., & Yeragani, V. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014489 · Cited by 58
Effectiveness and Safety of Benzodiazepines
Möller, H.-J. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00002 · Cited by 56
BEAUCLAIR, L., FONTAINE, R., ANNABLE, L., HOLOBOW, N., & CHOUINARD, G. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00005 · Cited by 56
Clonazepam in the treatment of social phobia: a pilot study.
Munjack, D. J., Baltazar, P. L., Bohn, P., CABE, D. D., & Appleton, A. A. (1990) · PubMed · Cited by 54
Strand, M., Hetta, J. E., Rosen, A., Sörensen, S., Malmström, R. E., Fabian, C. J., Marits, K., Vetterskog, K., Liljestrand, Ä., & Hegen, C. (1990) · PubMed · Cited by 52
PECKNOLD, J., LUTHE, L., MUNJACK, D., & ALEXANDER, P. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199410000-00005 · Cited by 46
Effects of clorazepate, diazepam, lorazepam, and placebo on human memory.
Healey, M. L., Pickens, R. W., Meisch, R. A., & McKenna, T. (1983) · PubMed · Cited by 45
A Comparison of Buspirone, Diazepam, and Placebo in Patients with Chronic Anxiety States
OLAJIDE, D., & LADER, M. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198706000-00005 · Cited by 42
Double-blind clonazepam vs placebo in panic disorder treatment
VALENÇA, A. M., NARDI, A. E., NASCIMENTO, I., MEZZASALMA, M. A., LOPES, F. L., & ZIN, W. (2000) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2000000600008 · Cited by 38
Lydiard, R. B., Jc, B., & Rickels, K. (1997) · PubMed · Cited by 32
Differential amnestic properties of short- and long-acting benzodiazepines.
Mb, S., Khosla, N., Brocker, N., & Goff, P. J. (1984) · PubMed · Cited by 32
Buspirone in the Treatment of Panic Disorder: A Controlled Pilot Comparison with Clorazepate
Schweizer, E. E., & Rickels, K. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198808000-00033 · Cited by 31
Controlled Comparison of Buspirone and Oxazepam in Generalized Anxiety
Ansseau, M., Papart, P., Gérard, M.-A., von Frenckell, R., & Franck, G. (1990) · Neuropsychobiology · doi:10.1159/000119464 · Cited by 29
Alprazolam and Diazepam in the Treatment of Generalized Anxiety
Elie, R., & Lamontagne, Y. (1984) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198406000-00002 · Cited by 29
Scavone, J. M., Greenblatt, D. J., Goddard, J. E., Friedman, H. L., Harmatz, J. S., & Shader, R. I. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00280132 · Cited by 29
The management of panic disorder.
Sheehan, D. V. (2002) · PubMed · Cited by 27
Benzodiazepine types in high versus therapeutic dose dependence
Nez‐Cano, H. M., Vela‐Bueno, A., Iceta, M. D., Pomalima, R., Martinez‐Gras, I., & Sobrino, M. P. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.91811799.x · Cited by 23
A Comparative Study of Suriclone, Lorazepam and Placebo in Anxiety Disorder
de Jonghe, F., Swinkels, J. A., Tuynman-Qua, H. G., & Jonkers, F. (1989) · Pharmacopsychiatry · doi:10.1055/s-2007-1014613 · Cited by 22
Roehrs, T., & Roth, T. G. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0074-1 · Cited by 22
Pourmotabbed, T., McLeod, D. R., Hoehn‐Saric, R., Hipsley, P. A., & Greenblatt, D. J. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606000-00002 · Cited by 21
Short-acting versus long-acting benzodiazepines: Discontinuation effects in panic disorders
Burrows, G. D., Norman, T. R., Judd, F. K., & Marriott, P. F. (1990) · Journal of Psychiatric Research · doi:10.1016/0022-3956(90)90037-q · Cited by 20
Therapeutic response to benzodiazepine in panic disorder subtypes
Valença, A. M., Nardi, A. E., Mezzasalma, M. A., Nascimento, I., Zin, W. A., Lopes, F. L., & Versiani, M. (2003) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802003000200009 · Cited by 20
Spénard, J., Caillé, G., Vezina, M., Larivière, L., Trudel, F., Ouellette, J., & de Montigny, C. (1988) · Biopharmaceutics & Drug Disposition · doi:10.1002/bod.2510090504 · Cited by 18
Treating anxiety while minimizing abuse and dependence.
Sussman, N. (1993) · PubMed · Cited by 16
Anxiety and addiction: a clinical perspective on comorbidity.
DuPont, R. L. (1995) · PubMed · Cited by 16
Self-citationControlled Trial of Dipotassium Clorazepate (‘Tranxene’) in Anxiety
Cooper, A. J., Magnus, R. V., Rose, M. R., Phanjoo, A. L., Lancaster, N. P., Pollard, P., & Knowlson, P. A. (1973) · The British Journal of Psychiatry · doi:10.1192/bjp.123.4.475 · Cited by 12
Magnus, R. V., Dean, B. C., & Curry, S. H. (1977) · PubMed · Cited by 11
Once‐a‐day Potassium Clorazepate in Anxiety
Magnus, R. V. (1973) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1973.tb09096.x · Cited by 11
A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY
Burrows, G. D., Dumovic, P., Smith, J. A., Norman, T. R., & Maguire, K. P. (1977) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1977.tb114618.x · Cited by 9
Donlon, P. T., & Singer, J. M. (1979) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1979.tb02483.x · Cited by 9
A Short Term Open Clinical Trial of Clobazam in the Treatment of Patients with Panic Attacks
Judd, F. K., Burrows, G. D., Marriott, P. F., & Norman, T. R. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198910000-00003 · Cited by 8
Alprazolam-XR: Dosage Considerations
Stahl, S. M. (1993) · Psychiatric Annals · doi:10.3928/0048-5713-19931002-08 · Cited by 8
Clorazepate dipotassium in anxiety: a double-blind trial with diazepam controls.
Wiersum, J. (1972) · PubMed · Cited by 8
Single daily dose treatment of anxiety with clobazam or dipotassium clorazepate.
Wallis, T., Valle‐Jones, J. C., Craven, J., Hanks, G., & Stonier, P. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb04679.x · Cited by 7
Lemoine, P., Rouillon, F., & Pouget, D. (1996) · PubMed · Cited by 6
Clorazepate Dipotassium in Anxiety: A Clinical Trial with Diazepam and Placebo Controls
RICCA, J. J. (1972) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1972.tb00057.x · Cited by 6
Pharmacokinetics of the benzodiazepines.
van Rooyen, J. M., & Offermeier, J. (1985) · PubMed · Cited by 6
Harris, P. G. (1975) · Current Medical Research and Opinion · doi:10.1185/03007997409111880 · Cited by 5
Schjønsby, H., Gordon, A. E., & Koeppen, D. (1979) · Journal of International Medical Research · doi:10.1177/030006057900700513 · Cited by 4
Alprazolam-XR: A Pharmacokinetic Review
Evans, R. L. (1993) · Psychiatric Annals · doi:10.3928/0048-5713-19931002-05 · Cited by 3
Once-Daily Control of Panic Disorder: Evidence From a Placebo-Controlled Study of Alprazolam-XR
Schweizer, E. E. (1993) · Psychiatric Annals · doi:10.3928/0048-5713-19931002-09 · Cited by 3
Henderson, J. G. (1982) · Scottish Medical Journal · doi:10.1177/003693308202700406 · Cited by 2
Gc, A., & De, O. (1980) · PubMed · Cited by 2
Economic costs of anxiety disorders
DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R., & Harwood, H. J. (1996) · Anxiety · doi:10.1002/(sici)1522-7154(1996)2:4<167::aid-anxi2>3.0.co;2-l
Self-citation
Research works printed but not linked: 9
- Rochiccioli P. Use of an anxiolytic agent: clobazam in children [in French]. Rev Int Pediatr 1977;59–62
- Disayavanish C Mahatnirunkul S Disayavanish P. Differential effects of three benzodiazepines in the treatment of neurotic patients. In: Hindmarch I Stonier PD Trimble M editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.81–8
- Harrison C Hindmarch I Clyde CA. A comparison of clobazam and diazepam in anxious patients. In: Hindmarch I Stonier PD Trimble M editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.89–100
- Thompson DJ. Comparison of drug treatment (clobazam) and relaxation therapy in the management of anxiety. Preliminary communication. In: Hindmarch I Stonier PD Trimble M editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.101–3
- DuPont RL, DuPont CM, DuPont Spencer E. Generalized anxiety disorder: a clinician’s guide to “the worry disease”. Dir Psychiatry 1999;XIX:133–45
- Siegfried K, Koeppen D, Taeuber K, Badian M, Malerczyk V, Sittig W. A double-blind comparison of the acute effects of clobazam and lorazepam on memory and psychomotor functions. Royal Soc Med Int Symp Ser 1981;43:13–21
- DuPont RL DuPont Spencer E DuPont CM. Anxiety and insomnia. In: The Anxiety Cure. An Eight-Step Program for Getting Well. Hoboken NJ: John Wiley & Sons; 2003. pp.200–6
- Kirkwood CK Melton ST. Anxiety disorders. In: Dipiro JT Talbert RL Yee GC Matzke GR Wells BG Posey LM editors. Pharmacotherapy: A Pathophysiologic Approach. 5th edn. Chicago: McGraw-Hill; 2002. pp.1289–310
- DuPont RL DuPont CM. Sedatives/hypnotics and benzodiazepines. In: Frances RJ Miller SI editors. Clinical Textbook of Addictive Disorders. New York: The Guilford Press; 1998. pp.120–49
Cited by
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
“These simulations were briefly described by Kaplan and DuPont (72), but detailed results are reported herein.”
BackgroundEarnheart, J. C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler, H., & Lüscher, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3609-06.2007 · Cited by 203
“GABAA receptors (GABAARs) are key control elements of anxiety states based on the anxiolytic properties of benzodiazepines (BZs), which act as allosteric GABAAR agonists (Mohler et al., 2002; Kaplan and DuPont, 2005).”
BackgroundBenzodiazepine Use and Misuse Among Patients in a Methadone Program
Chen, K. W., Berger, C. C., Forde, D. P., D'Adamo, C., Weintraub, E., & Gandhi, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-90 · Cited by 149
Altamura, A. C., Buoli, M., Albano, A., & DellʼOsso, B. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283384c74 · Cited by 134
Smith, A. J., & Tett, S. E. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-321 · Cited by 82
Metadata
- Authors
- Kaplan, E. M., & DuPont, R. L.
- Affiliations
- University of South Florida (US)
- Georgetown University (US)
- Corresponding author
- Kaplan, Eric Michael
- ORCID
- DuPont, Robert L.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2005-05-12
- Volume
- 21
- Issue
- 6
- Pages
- 941-950
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2137986275
- Cited by
- 55
- References
- 106
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 1 · 2022: 2 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 5 · 2014: 1 · 2013: 2 · 2012: 5
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- benzodiazepines, anxiety disorders, drug tolerance, benzodiazepine dependence, benzodiazepine withdrawal, sustained-release formulation, drug interactions
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Drug Tolerance, Humans, Practice Patterns, Physicians', Substance Withdrawal Syndrome, Anti-Anxiety Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.